Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2006-09-19
2006-09-19
Monshipouri, Maryam (Department: 1653)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C514S789000
Reexamination Certificate
active
07108851
ABSTRACT:
The present invention relates to the prevention and treatment of diseases associated with undesirable cell proliferation, including atherosclerotic narrowing of blood vessels and malignancy, comprising preventing or treating infection by mycoplasma. It is based, at least in part, on the discovery that, in many cases, mycoplasma infection exists coincident with undesirable cell proliferation and/or proliferation of other infectious organisms.
REFERENCES:
patent: 6281199 (2001-08-01), Gupta
Tsai et al., PNAS USA, 92(22), 10197-201, 1995.
Umezawa et al., “Enzyme-linked immunosorbent assay withTrypanosoma cruziexcreted-secreted antigens (TESA-ELISA) for serodiagnosis of acute and chronic Chagas' disease,”Diagn. Microbiol. Infect. Dis. 39:169-176, 2001 (USA).
Higuchi et al., “Great amount ofC. pneumoniaein ruptured plaque vessel segments at autopsy. A comparative study of stable plaques,”Ara. Bras. Cardiol. 74:149-151(2000).
Higuchi et al., “Detection ofMycoplasma pneumoniaeandChlamydia pneumoniaein ruptured atherosclerotic plaques,”Braz. J. Med. Biol. Res. 33:1023-1026 (2000).
Horne et al., “IgA sero-positivity toMycoplasma pneumoniaepredicts the diagnosis of coronary artery disease,”J. Am. Coll. Cardiol. 35:321 (abstract) (2000).
Laroy et al., “Cloning ofTrypanosoma cruzitrans-Sialidase and Expression inPichia pastoris,” Protein Expr. Purif. 20:389-393 (2000).
Buscaglia et al., “Tandem amino acid repeats fromTrypanosoma cruzished antigens increase the half-life of proteins in blood”, Blood, 93:2025-2032, (1999).
Cole, “Mycoplasma-induced arthritis in animals: relevance to understanding the etiologies of the human rheumatic diseases,”Rev. Rhum. Engl. Ed. 66 (1 Suppl):45S-49S (1999).
Berbec et al., “Total serum sialic acid concentration as a supporting marker of malignancy in ovarian neoplasia,”Eur J Gynaecol On col20(5-6): 389-392 (1999).
Feng Shaw-Huey, et al., “Mycoplasma infections prevent apoptosis and induce malignant transformation o interleuckin-3-dependent 32D hematopoietic cells,”Mol Cel Biol19(12): 7995-8002 (1999).
Nicolson et al., “Mycoplasmal infections in chronic illnesses,” (http://www.gulfwarvets.com/article24.htm) also published inMedical Sentinel, 4:172-175,191 (1999).
Ros-Bullon , et al., “Serum sialic acid in malignant melanoma patients: na ROC curve analysis,”Anticancer Res19(4C): 3619-3622 (1999).
Fu et al., “Middle cerebral artery occlusion after recentMycoplasma pneumoniaeinfection,”J. Neurol. Sci. 157:113-115 (1998).
Neyrolles et al., “Identification of two glycosylated components ofMycoplasma penetrans:a surface-exposed capsular polysaccharide and a glycolipid fraction,”Microbiology, 144:1247-1255 (1998).
Razin et al., “Molecular biology and pathogenicity of mycoplasmas,”Microbiol. Mol. Biol. Rev. 62(4):1094-1156 (1998).
Taylor-Robinson and Thomas, “Chlamydia pneumoniaein arteries: the facts, their interpretation, and future studies,”J. Clin. Pathol. 51:793-797 (1998).
Agusti et al., “The trans-sialidase ofTrypanosome cruziis anchored by two different lipids,”Glycobiology7(6):731-735 (1997).
Cole, “Mycoplasma interactions with the immune system: implications for disease pathology,” 1997, http://www.compkarori.com/arthritis/pil6002.htm).
Danesch et al., Chronic infecFarraj et al., “Mycoplasma-associated pericarditis, case report,”Mayo Clin. Proc. 72:33-36 (1997).
Farraj et al., “Mycoplasma-associated pericarditis, case report,”Mayo Clin. Proc. 72:33-36 (1997).
Gurfinkel et al., “IgG antibodies to chlamydial and mycoplasma infection plus C-reactive protein related to poor outcome in unstable angina,”Arch. Inst. Cardiol. Mex. 67:462-468 (1997).
Ribeirão et al., “Temperature differences for trans-glycosylation and hydrolysis reaction reveal an acceptor binding site in the catalytic mechanism ofTrypanosoma cruzitrans-sialidase,”Glycobiology7:1237-1246 (1997).tions and coronary artery disease: is there a link?,Lancet350:430-436 (1997).
Perez et al., “Leukocytoclastic vasculitis and polyarthritis associated withMycoplasma pneumoniaeinfection,”Clin. Infect. Dis. 25:154-155 (1997).
Trypanosoma cruzitrans-silaidase, Accession No. BAA09334, GI:840708,1060 aa, Smith et al. (1996).
Trypanosoma cruzitrans-silaidase, Accession No. BAA09333, GI:84706, 964 aa, Smith et al. (1996).
Buschiazzo et al., “Medium scale production and purification to homogeneity of a recombinant trans-sialidiase fromTrypanosoma cruzi,” Cell Mol. Biol. 42:703-710 (1996).
Cremona et al., “Effect of primary structure modifications inTrypanosoma cruzineuramindase trans-sialidase activities,”Cell. Mol. Biol. 42:697-702 (1996).
Umezawa et al., “Immunoblot assay using excreted/secreted antigens ofTrypanosoma cruziin serodiagnosis of congenital, acute and chronic Chagas' disease,”J. Clin. Microbiol. 34: 2143-2147, (1996).
Trypanosoma cruziTCTS-154 gene for trans-sialidase, Accession No. D50684, GI:840705, 2895 bp, Uemura et al. (1995).
Trypanosoma cruziTCTS-121 gene for trans-sialidase, Accession No. D50685, GI:840707, 3183 bp, Uemura et al. (1995).
Cremona et al., “A single tyrosine differentiates active and inactiveTrypanosome cruzitrans-sialidase,”Gene160:123-128 (1995).
Blanchard et al., “AIDS-associated mycoplasmas,”Annu. Rev. Microbiol. 48:687-712 (1994).
Campetella et al., “A recombinantTrypanosoma cruzitrans-sialidase lacking the amino acid repeats retains the enzymatic activity,”Mol. Biochem. Parasitol. 64:337-340 (1994).
Schenkman et al., “Structural and functional properties ofTrypanosometrans-sialidase,”Annu. Rev. Microbiol. 48:499-523 (1994).
Schenkman et al., “A proteolytic fragment ofTrypanosoma cruzitrans-sialidase lacking the carboxy-terminal domain is active, monomeric, and generates antibodies that inhibit enzymatic activity”J. Biol. Chem. 269:7970-7975 (1994).
Trypanosoma cruzitrans-sialidase homologue, Accession No. AAC98544, GI:624626, 736 aa, Briones et al.., (1993).
Scudder et al., “Enzymatic characterization of beta-D-galactoside alpha 2,3-trans-sialidase fromTrypanosome cruzi,” J. Biol. Chem. 268(13):9886-9891 (1993).
Trypanosoma cruzitrans-sialidase-neuraminidase, Accession No. S28409, GI:323067, 200 aa, Uemura et al., (1992).
Parodi et al., “Identification of the gene(s) coding for the trans-sialidase ofTrypanosome cruzi” EMBO J. 11:1705-1710 (1992).
Schenkman et al., “Trypanosoma cruzitrans-sialidase and neuraminidase activities can be mediated by the same enzymes,”J Exp Med175(2):567-575 (1992).
Uemura et al., “Only some members of a gene family inTrypanosome cruziencode proteins that express both trans-sialidase and neuraminidase activities,”EMBO J. 11:3837-3844 (1992).
Vandekerckhove et al., “Substrate specificity of theTrypanosoma cruzitrans-sialidase,”Glycobiology2(6):541-548, (1992).
Pereira et al., “TheTrypanosoma cruzineuraminidase contains sequences similiar to bacterial neuraminidases, YWTD repeats of the low density lipoprotein receptor, and Type III modules of fibronection,”J. Ex. Med. 174:179-191 (1991).
Pollevick et al., “The complete sequence of a shed acute-phase antigen ofTrpanosoma cruzi,” Mol. Biochem. Parasitol. 47:247-250 (1991).
Schenkman et al., “Attachment ofTrypanosoma cruzitrypomastigotes to receptors at restricted cell surface domains,”Exp. Parasitol. 72:76-86 (1991).
Roberts et al., “Sialic Acid-dependent Adhesion ofMycoplasma pneumoniaeto Purified Glycoproteins,”Journal of Biological Chemistry, 264:9289-9293 (1989).
Chen et al., “Carditis associated withMycoplasma pneumoniaeinfection,”Am. J. Dis. Child. 140:471-472 (1986).
Pereira, “A developmentally regulated neuraminidase activity i
Higuchi Maria De Lourdes
Schenkman Sergio
Baker & Botts LLP
Monshipouri Maryam
LandOfFree
Prevention and treatment of mycoplasma-associated diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of mycoplasma-associated diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of mycoplasma-associated diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3585736